What question did this study set out to answer?

To analyze the pharmacokinetics and exposure-response relationships of nemtabrutinib in patients with hematologic malignancies.

May 4, 2026

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates response to nemtabrutinib in hematologic malignancies, indicating a suitable dosage.

To analyze the pharmacokinetics and exposure-response relationships of nemtabrutinib in patients with hematologic malignancies.
Developed a population pharmacokinetic model using data from 578 patients in phase 1 and 2 studies.
Utilized a two-compartment model with first-order absorption and elimination for data analysis.
Evaluated the impact of covariates such as body weight, sex, race, and age on drug clearance and bioavailability.
Final model showed no significant impact of intrinsic factors on nemtabrutinib pharmacokinetics.
Increased exposure correlated with better overall response in patients with chronic lymphocytic leukemia.
Identified 65 mg daily as an appropriate dose for nemtabrutinib monotherapy based on exposure-response analyses.

Kemal et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark